Search

Your search keyword '"Kremens, B"' showing total 358 results
Start Over Author "Kremens, B"
358 results on '"Kremens, B"'

1. Extended induction chemotherapy does not improve the outcome for high-risk neuroblastoma patients: results of the randomized open-label GPOH trial NB2004-HR

Author

Berthold, F., Faldum, A., Ernst, A., Boos, J., Dilloo, D., Eggert, A., Fischer, M., Frühwald, M., Henze, G., Klingebiel, T., Kratz, C., Kremens, B., Krug, B., Leuschner, I., Schmidt, M., Schmidt, R., Schumacher-Kuckelkorn, R., von Schweinitz, D., Schilling, F.H., Theissen, J., Volland, R., Hero, B., and Simon, T.

Published
2020
Full Text
View/download PDF

12. Allo-SCT using BU, CY and melphalan for children with AML in second CR

Author

Beier, R, Albert, M H, Bader, P, Borkhardt, A, Creutzig, U, Eyrich, M, Ehlert, K, Gruhn, B, Greil, J, Handgretinger, R, Holter, W, Klingebiel, T, Kremens, B, Lang, P, Mauz-Körholz, C, Meisel, R, Müller, I, Peters, C, Reinhardt, D, Sedlacek, P, Schulz, A, Schuster, F R, Schrauder, A, Strahm, B, Sykora, K W, Wössmann, W, Zimmermann, M, and Sauer, M G

Published
2013
Full Text
View/download PDF

16. CLINICAL IMPACT OF POST-TRANSPLANT CHIMERISM MONITORING IN CD33/34 BONE MARROW SUBPOPULATIONS AND WHOLE PERIPHERAL BLOOD IN PEDIATRIC AML: PROSPECTIVE COMPARISON OF HIGHLY SENSITIVE REAL TIME SEQUENCE POLYMORPHISM PCR VERSUS GOLD-STANDARD STR-PCR: PH-O097

Author

Willasch, Manfred A., Rettinger, E., Zabel, M., Kreyenberg, H., Meyer, V., Merker, M., Borkhardt, A., Metzler, M., Kremens, B., Strahm, B., Woessmann, W., Mauz-Koerholz, C., Gruhn, B., Burdach, S., Albert, M., Schlegel, P.-G., Klingebiel, T., and Bader, P.

Published
2014

20. Metalloenzymes

Author

Pollard, J. W., Danilkovitch-Miagkova, A., Minaguchi, T., Waite, K. A., Buys, T. P. H., Lam, W. L., Müller-Hermelink, H. K., Ott, G., Robb, V. A., Henske, E. P., Lynge, E., Boyd, N., Geisler, C., Seger, R., De Wolf-Peeters, C., Sagaert, X., Sheng, S., Ribatti, D., Verstovsek, S., Akin, C., Stack, M. S., Kitada, S., Gartenhaus, R., Moretti, F., Frühwald, Michael C., Mooi, W. J., Krausz, T., Kefford, R., Peikert, T., Specks, U., Tueting, T., Pföhler, C., Blask, D. E., Stevens, R. G., Nies, A. T., Gotoh, N., Tsuchida, N., Escriba, P., Singh, V., Hickey, M., Saunders, C., Xiao, G.-H., Testa, J. R., Furtwängler, R., Scholler, N., Carbone, M., Furge, K., Woude, G. F. V., Roland, W. C., Muschel, R., Hunter, K., Welch, D. R., Vaidya, K. S., Hurst, D. R., Silveira, A. C., Zang, X. A., Bari, R., Silveira, A., Szmulewitz, R., Taylor, J., Rinker-Schaffer, C., Shim, H., Plass, C., Lindsey, J. C., Clifford, S. C., Holdenrieder, S., Steinle, A., Salih, H., Brown, D. A., Breit, S. N., Bauskin, A. R., Mousses, S., Lung, M. L., Alix-Panabieres, C., Pantel, K., Djuzenova, C. S., Dalmay, T., Ahlquist, T., Lothe, R. A., Bhat, K., Setaluri, V., Rutka, J. T., Salhia, B., Cockell, K. A., Radich, J. P., Yamagishi, S.-I., Bignami, M., Verma, M., Kumar, D., Brenner, C., Zhang, Y.-W., Jamieson, D., Chi, Y.-H., Jeang, K.-T., Roninson, I., Dragani, T., Sobolev, A. S., Powers, M. V., Workmann, P., Evans, M. F., Cooper, K., Kausch, I., Doehn, C., Janz, S., Huang, C.-L., Toland, A. E., Osinaga, E., Kaye, F., Lemos, M. C., Thakker, R. V., Teh, B. T., Ponder, B. A. J., Mulligan, L. M., Gullo, C., Klein, G., Wu, X., Araten, D. J., Loeb, L. A., Cheadle, J. P., Lipsick, J., Albihn, A., Henriksson, M., Kremens, B., Germing, U., Zangemeister-Wittke, U., Simon, H.-U., Yu, Y. P., Luo, J., and Aman, P.

Published
2020

21. Metallothionein enzymes

Author

Pollard, J. W., Danilkovitch-Miagkova, A., Minaguchi, T., Waite, K. A., Buys, T. P. H., Lam, W. L., Müller-Hermelink, H. K., Ott, G., Robb, V. A., Henske, E. P., Lynge, E., Boyd, N., Geisler, C., Seger, R., De Wolf-Peeters, C., Sagaert, X., Sheng, S., Ribatti, D., Verstovsek, S., Akin, C., Stack, M. S., Kitada, S., Gartenhaus, R., Moretti, F., Frühwald, Michael C., Mooi, W. J., Krausz, T., Kefford, R., Peikert, T., Specks, U., Tueting, T., Pföhler, C., Blask, D. E., Stevens, R. G., Nies, A. T., Gotoh, N., Tsuchida, N., Escriba, P., Singh, V., Hickey, M., Saunders, C., Xiao, G.-H., Testa, J. R., Furtwängler, R., Scholler, N., Carbone, M., Furge, K., Woude, G. F. V., Roland, W. C., Muschel, R., Hunter, K., Welch, D. R., Vaidya, K. S., Hurst, D. R., Silveira, A. C., Zang, X. A., Bari, R., Silveira, A., Szmulewitz, R., Taylor, J., Rinker-Schaffer, C., Shim, H., Plass, C., Lindsey, J. C., Clifford, S. C., Holdenrieder, S., Steinle, A., Salih, H., Brown, D. A., Breit, S. N., Bauskin, A. R., Mousses, S., Lung, M. L., Alix-Panabieres, C., Pantel, K., Djuzenova, C. S., Dalmay, T., Ahlquist, T., Lothe, R. A., Bhat, K., Setaluri, V., Rutka, J. T., Salhia, B., Cockell, K. A., Radich, J. P., Yamagishi, S.-I., Bignami, M., Verma, M., Kumar, D., Brenner, C., Zhang, Y.-W., Jamieson, D., Chi, Y.-H., Jeang, K.-T., Roninson, I., Dragani, T., Sobolev, A. S., Powers, M. V., Workmann, P., Evans, M. F., Cooper, K., Kausch, I., Doehn, C., Janz, S., Huang, C.-L., Toland, A. E., Osinaga, E., Kaye, F., Lemos, M. C., Thakker, R. V., Teh, B. T., Ponder, B. A. J., Mulligan, L. M., Gullo, C., Klein, G., Wu, X., Araten, D. J., Loeb, L. A., Cheadle, J. P., Lipsick, J., Albihn, A., Henriksson, M., Kremens, B., Germing, U., Zangemeister-Wittke, U., Simon, H.-U., Yu, Y. P., Luo, J., and Aman, P.

Published
2020

30. Second German consensus on immunogenetic donor search for allotransplantation of hematopoietic stem cells

Author

Ottinger, H., Müller, C., Goldmann, S., Albert, E., Arnold, R., Beelen, D., Blasczyk, R., Bunjes, D., Casper, J., Ebell, W., Ehninger, G., Eiermann, T., Einsele, H., Fauser, A., Ferencik, S., Finke, J., Hertenstein, B., Heyll, A., Klingebiel, T., Knipper, A., Kremens, B., Kolb, H., Kolbe, K., Lenartz, E., Lindemann, M., Müller, C., Mytilineos, J., Niederwieser, D., Runde, V., Sayer, H., Schaefer, U., Schmitz, N., Schröder, S., Schulze-Rath, R., Schwerdtfeger, R., Siegert, W., Thiele, B., Zander, A., and Grosse-Wilde, H.

Published
2001
Full Text
View/download PDF

44. Allogeneic and Autologous Bone Marrow Transplantation in Acute Leukemia: The Essen Experience

Author

Schaefer, U. W., primary, Beelen, D. W., additional, Graeven, U., additional, Kölbel, M., additional, Sayer, H., additional, Quabeck, K., additional, Becher, R., additional, Kremens, B., additional, Stollmann, B., additional, Grosse-Wilde, H., additional, Molls, M., additional, Quast, U., additional, Szy, D., additional, Haralambie, E., additional, Ansorg, R., additional, Thraenhart, O., additional, and Luboldt, W., additional

Published
1990
Full Text
View/download PDF

45. Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: Results from a phase III trial

Author

Suttorp, M, Schulze, P, Glauche, I, Göhring, G, Von Neuhoff, N, Metzler, M, Sedlacek, P, De Bont, E, Balduzzi, A, Lausen, B, Aleinikova, O, Sufliarska, S, Henze, G, Strauss, G, Eggert, A, Kremens, B, Groll, A, Berthold, F, Klein, C, Groß-Wieltsch, U, Sykora, K, Borkhardt, A, Kulozik, A, Schrappe, M, Nowasz, C, Krumbholz, M, Tauer, J, Claviez, A, Harbott, J, Kreipe, H, Schlegelberger, B, Thiede, C, Suttorp, Meinolf, Schulze, Philipp, Glauche, Ingmar, Göhring, Gudrun, Von Neuhoff, Nils, Metzler, Markus, Sedlacek, Petr, De Bont, Eveline S. J. M., Balduzzi, Adriana, Lausen, Birgitte, Aleinikova, Olga, Sufliarska, Sabina, Henze, Günter, Strauss, Gabriele, Eggert, Angelika, Kremens, Bernhard, Groll, Andreas H., Berthold, Frank, Klein, Christoph, Groß-Wieltsch, Ute, Sykora, Karl Walter, Borkhardt, Arndt, Kulozik, Andreas E., Schrappe, Martin, Nowasz, Christina, Krumbholz, Manuela, Tauer, Josephine T., Claviez, Alexander, Harbott, Jochen, Kreipe, Hans H., Schlegelberger, Brigitte, Thiede, Christian, Suttorp, M, Schulze, P, Glauche, I, Göhring, G, Von Neuhoff, N, Metzler, M, Sedlacek, P, De Bont, E, Balduzzi, A, Lausen, B, Aleinikova, O, Sufliarska, S, Henze, G, Strauss, G, Eggert, A, Kremens, B, Groll, A, Berthold, F, Klein, C, Groß-Wieltsch, U, Sykora, K, Borkhardt, A, Kulozik, A, Schrappe, M, Nowasz, C, Krumbholz, M, Tauer, J, Claviez, A, Harbott, J, Kreipe, H, Schlegelberger, B, Thiede, C, Suttorp, Meinolf, Schulze, Philipp, Glauche, Ingmar, Göhring, Gudrun, Von Neuhoff, Nils, Metzler, Markus, Sedlacek, Petr, De Bont, Eveline S. J. M., Balduzzi, Adriana, Lausen, Birgitte, Aleinikova, Olga, Sufliarska, Sabina, Henze, Günter, Strauss, Gabriele, Eggert, Angelika, Kremens, Bernhard, Groll, Andreas H., Berthold, Frank, Klein, Christoph, Groß-Wieltsch, Ute, Sykora, Karl Walter, Borkhardt, Arndt, Kulozik, Andreas E., Schrappe, Martin, Nowasz, Christina, Krumbholz, Manuela, Tauer, Josephine T., Claviez, Alexander, Harbott, Jochen, Kreipe, Hans H., Schlegelberger, Brigitte, and Thiede, Christian

Abstract

A total of 156 patients (age range 1.3-18.0 years, median 13.2 years; 91 (58.3%) male) with newly diagnosed CML (N = 146 chronic phase (CML-CP), N = 3 accelerated phase (CML-AP), N = 7 blastic phase (CML-BP)) received imatinib up-front (300, 400, 500 mg/m 2 , respectively) within a prospective phase III trial. Therapy response, progression-free survival, causes of treatment failure, and side effects were analyzed in 148 children and adolescents with complete data. Event-free survival rate by 18 months for patients in CML-CP (median follow-up time 25 months, range: 1-120) was 97% (95% CI, 94.2-99.9%). According to the 2006 ELN-criteria complete hematologic response by month 3, complete cytogenetic response (CCyR) by month 12, and major molecular response (MMR) by month 18 were achieved in 98, 63, and 59% of the patients, respectively. By month 36, 86% of the patients achieved CCyR and 74% achieved MMR. Thirty-eight patients (27%) experienced imatinib failure because of unsatisfactory response or intolerance (N = 9). In all, 28/148 patients (19%) underwent stem cell transplantation (SCT). In the SCT sub-cohort 2/23 patients diagnosed in CML-CP, 0/1 in CML-AP, and 2/4 in CML-BP, respectively, died of relapse (N = 3) or SCT-related complications (N = 2). This large pediatric trial extends and confirms data from smaller series that first-line imatinib in children is highly effective.

Published
2018

48. Randomised Introduction of 2-CDA as Intensification during Consolidation for Children with High-risk AML--results from Study AML-BFM 2004

Author

Creutzig, U, Dworzak, M, Zimmermann, M, Bourquin, J-P, Gruhn, B, Fleischhack, G, Graf, N, Klingebiel, T, Kremens, B, Lehrnbecher, T, von Neuhoff, C, von Stackelberg, A, Stray, J, Reinhardt, D, University of Zurich, and Creutzig, U

Subjects
10036 Medical Clinic, 610 Medicine & health, 2735 Pediatrics, Perinatology and Child Health
Published
2015
Full Text
View/download PDF

49. Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000

Author

Moricke, A., Zimmermann, M., Valsecchi, M. G., Stanulla, M., Biondi, A., Mann, G., Locatelli, Franco, Cazzaniga, G., Niggli, F., Arico, M., Bartram, C. R., Attarbaschi, A., Silvestri, D., Beier, R., Basso, G., Ratei, R., Kulozik, A. E., Lo Nigro, L., Kremens, B., Greiner, J., Parasole, R., Harbott, J., Caruso, R., von Stackelberg, A., Barisone, E., Rossig, C., Conter, V., Schrappe, M., Locatelli F. (ORCID:0000-0002-7976-3654), Moricke, A., Zimmermann, M., Valsecchi, M. G., Stanulla, M., Biondi, A., Mann, G., Locatelli, Franco, Cazzaniga, G., Niggli, F., Arico, M., Bartram, C. R., Attarbaschi, A., Silvestri, D., Beier, R., Basso, G., Ratei, R., Kulozik, A. E., Lo Nigro, L., Kremens, B., Greiner, J., Parasole, R., Harbott, J., Caruso, R., von Stackelberg, A., Barisone, E., Rossig, C., Conter, V., Schrappe, M., and Locatelli F. (ORCID:0000-0002-7976-3654)

Abstract

Induction therapy for childhood acute lymphoblastic leukemia (ALL) traditionally includes prednisone; yet, dexamethasone may have higher antileukemic potency, leading to fewer relapses and improved survival. After a 7-day prednisone prephase, 3720 patients enrolled on trial Associazione Italiana di Ematologia e Oncologia Pediatrica and Berlin-Frankfurt-Münster (AIEOP-BFM) ALL 2000 were randomly selected to receive either dexamethasone (10 mg/m(2) per day) or prednisone (60 mg/m(2) per day) for 3 weeks plus tapering in induction. The 5-year cumulative incidence of relapse (± standard error) was 10.8 ± 0.7% in the dexamethasone and 15.6 ± 0.8% in the prednisone group (P < .0001), showing the largest effect on extramedullary relapses. The benefit of dexamethasone was partially counterbalanced by a significantly higher induction-related death rate (2.5% vs 0.9%, P = .00013), resulting in 5-year event-free survival rates of 83.9 ± 0.9% for dexamethasone and 80.8 ± 0.9% for prednisone (P = .024). No difference was seen in 5-year overall survival (OS) in the total cohort (dexamethasone, 90.3 ± 0.7%; prednisone, 90.5 ± 0.7%). Retrospective analyses of predefined subgroups revealed a significant survival benefit from dexamethasone only for patients with T-cell ALL and good response to the prednisone prephase (prednisone good-response [PGR]) (dexamethasone, 91.4 ± 2.4%; prednisone, 82.6 ± 3.2%; P = .036). In patients with precursor B-cell ALL and PGR, survival after relapse was found to be significantly worse if patients were previously assigned to the dexamethasone arm. We conclude that, for patients with PGR in the large subgroup of precursor B-cell ALL, dexamethasone especially reduced the incidence of better salvageable relapses, resulting in inferior survival after relapse. This explains the lack of benefit from dexamethasone in overall survival that we observed in the total cohort except in the subset of T-cell ALL patients with PGR. This trial was registered at www

Published
2016

50. Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000

Author

Möricke, A, Zimmermann, M, Valsecchi, M, Stanulla, M, Biondi, A, Mann, G, Locatelli, F, Cazzaniga, G, Niggli, F, Aricò, M, Bartram, C, Attarbaschi, A, Silvestri, D, Beier, R, Basso, G, Ratei, R, Kulozik, A, Lo Nigro, L, Kremens, B, Greiner, J, Parasole, R, Harbott, J, Caruso, R, von Stackelberg, A, Barisone, E, Rössig, C, Conter, V, Schrappe, M, Möricke, A, Zimmermann, M, Valsecchi, M, Stanulla, M, Biondi, A, Mann, G, Locatelli, F, Cazzaniga, G, Niggli, F, Aricò, M, Bartram, C, Attarbaschi, A, Silvestri, D, Beier, R, Basso, G, Ratei, R, Kulozik, A, Lo Nigro, L, Kremens, B, Greiner, J, Parasole, R, Harbott, J, Caruso, R, von Stackelberg, A, Barisone, E, Rössig, C, Conter, V, and Schrappe, M

Abstract

Induction therapy for childhood acute lymphoblastic leukemia (ALL) traditionally includes prednisone; yet, dexamethasone may have higher antileukemic potency, leading to fewer relapses and improved survival. After a 7-day prednisone prephase, 3720 patients enrolled on trial Associazione Italiana di Ematologia e Oncologia Pediatrica and Berlin-Frankfurt-Münster (AIEOP-BFM) ALL 2000 were randomly selected to receive either dexamethasone (10 mg/m(2) per day) or prednisone (60 mg/m(2) per day) for 3 weeks plus tapering in induction. The 5-year cumulative incidence of relapse (± standard error) was 10.8 ± 0.7% in the dexamethasone and 15.6 ± 0.8% in the prednisone group (P < .0001), showing the largest effect on extramedullary relapses. The benefit of dexamethasone was partially counterbalanced by a significantly higher induction-related death rate (2.5% vs 0.9%, P = .00013), resulting in 5-year event-free survival rates of 83.9 ± 0.9% for dexamethasone and 80.8 ± 0.9% for prednisone (P = .024). No difference was seen in 5-year overall survival (OS) in the total cohort (dexamethasone, 90.3 ± 0.7%; prednisone, 90.5 ± 0.7%). Retrospective analyses of predefined subgroups revealed a significant survival benefit from dexamethasone only for patients with T-cell ALL and good response to the prednisone prephase (prednisone good-response [PGR]) (dexamethasone, 91.4 ± 2.4%; prednisone, 82.6 ± 3.2%; P = .036). In patients with precursor B-cell ALL and PGR, survival after relapse was found to be significantly worse if patients were previously assigned to the dexamethasone arm. We conclude that, for patients with PGR in the large subgroup of precursor B-cell ALL, dexamethasone especially reduced the incidence of better salvageable relapses, resulting in inferior survival after relapse. This explains the lack of benefit from dexamethasone in overall survival that we observed in the total cohort except in the subset of T-cell ALL patients with PGR. This trial was registered at www.cl

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results